Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2004.039636v1, 2004; 10.1373/clinchem.2004.039636
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.039636v1
51/1/84    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baumgart, Y.
Right arrow Articles by Birkenmeier, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baumgart, Y.
Right arrow Articles by Birkenmeier, G.

Received on July 6, 2004
Accepted on September 24, 2004

Cancer Diagnostics

Characterisation of Novel Monoclonal Antibodies for Prostate-Specific Antigen (PSA) with Potency to Recognize PSA Bound to {alpha}2-Macroglobulin

Yvonne Baumgart 1, Andreas Otto 1, Angelika Schäfer 1, Elke Usbeck 1, Christiane Cott 1, Astrid Schott 1, Maria Tornack 1, Anett Wenzel 1, Andualem Mossie 1, Gerd Birkenmeier 1*

1 Institute of Biochemistry, University of Leipzig, Liebigstrasse 16, 04103 Leipzig, Germany

* To whom correspondence should be addressed. E-mail: birg{at}medizin.uni-leipzig.de.

Background: Different molecular forms of prostate-specific antigen (PSA) have been used to differentiate between benign prostatic hyperplasia and prostate cancer. Detecting PSA bound to endogenous inhibitors such as {alpha}1-antichymotrypsin (ACT) and {alpha}2-macroglobulin ({alpha}2M) is often difficult because of epitope masking or sensitivity problems. Here we report the characterization of four novel mouse monoclonal antibodies (mabs) obtained by immunization with PSA-{alpha}2M complexes. Their ability to detect free PSA and PSA-inhibitor complexes was shown, and their epitopes were analyzed by phage display technology.

Methods: The properties of the mabs were studied by competition and sandwich assays and by Western blotting. Epitope mapping was performed by screening of a phage display peptide library.

Results: All four mabs recognized free PSA, PSA-ACT, and PSA-{alpha}2M complexes but to various degrees. With different combinations of mabs in competition experiments, antibodies were identified that enhance binding of other mabs to PSA, forming the molecular basis of a very sensitive assay for the detection of PSA and PSA-ACT complexes. Mabs with highest reactivity for PSA-{alpha}2M were selected to establish an immunoassay for that complex. Western blot analysis revealed the all mabs recognized conformational epitopes of PSA. These findings were supported by phage display results demonstrating mimotopes in the PSA molecule.

Conclusions: The results presented here could aid in the further development of clinically relevant assays for PSA and PSA-{alpha}2M complexes.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by the American Association for Clinical Chemistry.